31P magnetic resonance spectroscopy in hypertensives with left ventricle hypertrophy - assessment of energy metabolism

Assess the state of myocardial energy metabolism in patients with arterial hypertension (AH) and left ventricular hypertrophy (LVH) according to 31P magnetic resonance spectroscopy (31P MRS) compared with healthy individuals. The study included 46 people, 30 healthy volunteers (group I) who do not have cardiovascular disease (CVD) and 16 hypertensive patients with LVH (group II). All persons included in the study was performed MRI and MRS of the heart on high field MRI Achieva 3T TX (Philips, The Netherlands). We used the ISIS localization, adiabatic impulse with iterative shimming. To assess myocardial energy metabolism in patients with hypertension and LVH we used two energy indexs: PCr/ATP (the ratio of the concentrations of phosphocreatine to adenosine triphosphate), and Pi/PCr (the ratio of the concentration of inorganic phosphate to phosphocreatine). Index value of PCr/ATP in the group I was 2.08±0.35, in group II - 1.66±0.11, (p <0.05). The value of Pi/PCr in group I was 8.87±3.14, in group II - 13.5±3.3 (p<0.05). 31P MRS can be used to determine the status of myocardial energy metabolism in patients with hypertension and LVH.

магнитно-резонансная спектроскопия, 31Р, метаболизм миокарда, фосфокреатин, аденозинтрифосфат, АТФ, артериальная гипертония, гипертрофия миокарда, magnetic resonance spectroscopy, 31P, myocardial metabolism, phosphocreatine, adenosine triphosphate, ATP, arterial hypertension, left ventricle hypertrophy

1. Беленков Ю. Н. и др. Гипертрофическая кардиомиопатия исторические и современные взгляды на диагностику заболевания // Кардиология и сердечно-сосудистая хирургия. 2008. № 4. С. 4-10.

2. Чазова И. Е. Артериальная гипертония: стандарты сегодняшнего дня и нерешенные проблемы // Сердце. 2002. № 1. С. 217-219.

3. Balaban R. S. Regulation of oxidative phosphorylation in the mammalian cell // Am. J. Physiol. 1990. № 258. Р. C377-C389.

4. Beer M. Cardiac spectroscopy: techniques, indications and clinical results // Eur. Radiol. 2004. № 14. Р. 1034-1047.

5. Bottomley P. A. MR spectroscopy of the human heart: the status and the challenges // Radiology. 1994. № 191. Р. 593-612.

6. Camici P. et al. Coronary vasodilatation is impaired in both hypertrophied and non-hypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron tomography // J. Am. Coll. Cardiol. 1991. № 17. Р. 879-886.

7. Conway M. A. et al. Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy //Lancet. 1991. № 338. Р. 973-976.

8. Conway M. A. et al. Cardiac metabolism during exercise measured by magnetic resonance spectroscopy // Lancet. 1988. № 2. Р. 692.

9. de Roos A. et al. Cardiac metabolism in patients with dilated and hypertrophic cardiomyopathy: assessment with proton-decoupled P-31 MR spectroscopy // J. Magn. Reson. Imaging. 1992. № 2. Р. 711-719.

10. Devereux R. B. et al. Left ventricular hypertrophy and geometric remodeling in hypertension: stimuli, functional consequense and prognostic implications // J. Hypertens. 1994. Vol. 12. Suppl. P. 117-127.

11. Goodwin G. W., Ahmad F., Taegtmeyer H. Preferential oxidation of glycogen in isolated working rat heart // J. Clin. Invest. 1996. № 97. Р. 1409 -1416.

12. Hansch A. R. et al. Jena/DE Noninvasive measurement of cardiac high-energy phosphate metabolites using 31P-spectroscopic chemical shift imaging // ECR. 2009. e-Poster: Р. C-174.

13. Heyne J.-R. et al. Kaiser 31P-MR spectroscopic imaging in hypertensive heart disease // Eur. Radiol. 2006. № 16. Р. 1796-1802.

14. Kannel W. B. Left ventricular hypertrophy as a risk factor // J. Hypertens. 1991. № 9. Suppl. 2. Р. S3-S9.

15. Kostler H. et al. Age and gender dependence of human cardiac phosphorus metabolites determined by SLOOP 31P MR spectroscopy // Magn. Reson. Med. 2006. № 56. Р. 907-911.

16. Lamb H. J. et al. Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism // Circulation. 1999. № 99. Р. 2261-2267.

17. Loffler R. et al. Localized spectroscopy from anatomically matched compartments: improved sensitivity and localization for cardiac 31P MRS in humans // J. Magn. Reson. 1998. № 134. Р. 287-299.

18. Lortet S. et al. Alteration of cardiac energy state during development of hypertension in rats of the Lyon strain: a 31P-NMR study on the isolated rat heart // Acta Physiol. Scand. 1993. № 149. Р. 311-321.

19. Maron B. J. Hypertrophic cardiomyopathy // Lancet. 1997. Vol. 350. P. 127-133.

20. Maron B. J., Epstein S. E., Roberts W. C. Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries // Am. J. Cardiol. 1979. № 43. Р. 1086-1102.

21. Massie B. M. et al. Myocardial high-energy phosphate and substrate metabolism in swine with moderate left ventricular hypertrophy // Circulation. 1995. № 91. Р. 1814-1823.

22. Miller D. D., Walsh R. A. In vivo phosphorus-31 NMR spectroscopy of abnormal myocardial high-energy phosphate metabolism during cardiac stress in hypertensive- hypertrophied non-human primates // Int. J. Card. Imaging. 1990-1991. № 6. Р. 57-70.

23. Neubauer S. et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy // Circulation. 1997. № 96. Р. 2190-2196.

24. Neubauer S. Cardiac magnetic resonance spectroscopy: potential clinical applications // Herz. 2000. № 25. Р. 452-460.

25. Neubauer S. et al. Cardiac high-energy phosphate metabolism in patients with aortic valve disease assessed by 31P-magnetic resonance spectroscopy // J. Investig. Med. 1997. № 45. Р. 453-462.

26. Neubauer S. The failing heart an engine out of fuel // N. Engl. J. Med. 2007. № 356 (11). Р. 1140-1151.

27. Nienaber C. A. Regional myocardial bloodflow and glucose utilization in symptomatic patients with hypertrophic cardiomyopathy // Circulation. 1993. № 87. Р. 1580-1590.

28. Okada M. et al. Influence of aging or left ventricular hypertrophy on the human heart: contents of phosphorus metabolites measured by 31P MRS // Magn. Reson. Med. 1998. № 39, Р. 772-782.

29. Osbakken M. et al. Creatine kinase kinetics studied by phosphorus-31 nuclear magnetic resonance in a canine model of chronic hypertension-induced cardiac hypertrophy // J. Am. Coll. Cardiol. 1992. № 19. Р. 223-228.

30. Schaefer S. et al. Relationship between myocardial metabolites and contractile abnormalities during graded regional ischemia // J. Clin. Invest. 1990. № 85. Р. 706-713.

31. Schocke M. F. et al. Impact of aging on cardiac high-energy phosphate metabolism determined by phosphorus-31 2-dimensional chemical shift imaging (31P 2D CSI) // Magn. Reson. Imaging. 2003. № 21. Р. 553-559.

32. Schulman D. S. et al. Antihypertensive treatment in hypertensive patients with normal left ventricular mass is associated with normal left ventricular remodeling and improved diastolic function // Am. J. Cardiol. 1996. № 78. Р. 56-60.

33. Shivu G. N. et al. 31P magnetic resonance spectroscopy to measure in vivo cardiac energetics in normal myocardium and hypertrophic cardiomyopathy: Experiences at 3 T // Eur. J. Radiol. 2008.

34. Smith V. et al. Rapid ventricular filling in left ventricular hypertrophy, II: pathologic hypertrophy // J. Am. Coll. Cardiol. 1985. № 5. Р. 869-874.

35. Spindler M. et al. Diastolic dysfunction and altered energetics in the aMHC403/1 mouse model of familial hypertrophic cardiomyopathy // J. Clin. Invest. 1998. № 101. Р. 1775-1783.

36. Zhang J. et al. Effect of left ventricular hypertrophy secondary to chronic pressure overload on transmural myocardial 2-deoxyglucose uptake: a 31P NMR spectroscopic study // Circulation. 1995. № 92. Р. 1274-1283.

37. Zhang J. et al. Bioenergetic abnormalities associated with severe left ventricular hypertrophy // J. Clin. Invest. 1993. № 92. Р. 993-1003.